Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results
April 25 2023 - 7:00AM
Business Wire
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or
the “Company”), a leading global eye health company dedicated to
helping people see better to live better, today announced the
election of the 10 directors nominated at its 2023 annual meeting
of shareholders (the “Annual Meeting”) held on April 24, 2023. The
detailed results of the vote for the election of directors are set
out below:
Name
For
Against
Broker Non-Votes
Nathalie Bernier
344,100,848
124,733
2,315,925
Richard U. De Schutter
344,094,979
130,602
2,315,925
Gary Hu
344,016,782
208,799
2,315,925
Brett Icahn
344,072,707
152,874
2,315,925
Sarah B. Kavanagh
343,989,666
235,915
2,315,925
John A. Paulson
344,095,439
130,142
2,315,925
Russel C. Robertson
344,098,056
127,525
2,315,925
Thomas W. Ross, Sr.
340,211,351
4,014,230
2,315,925
Brenton L. Saunders
342,408,245
1,817,336
2,315,925
Andrew C. von Eschenbach, M.D.
343,985,915
239,666
2,315,925
At the Annual Meeting, shareholders also approved, in a
non-binding advisory vote, the compensation of the Company’s named
executive officers and the frequency of future advisory votes on
named executive officer compensation being one year, approved an
amendment and restatement of the Company’s 2022 Omnibus Incentive
Plan (the “Plan”) to increase the number of common shares
authorized for issuance thereunder, and appointed
PricewaterhouseCoopers LLP as the Company’s independent registered
public accounting firm until the close of the Company's 2024 annual
meeting of shareholders.
For the purposes of Toronto Stock Exchange (“TSX”) approval with
respect to the Plan, the Company relied on the exemption set forth
in Section 602.1 of the TSX Company Manual, which provides that the
TSX will not apply its standards to certain transactions involving
eligible inter-listed issuers on a recognized exchange, such as the
NYSE.
The final vote tabulation on all matters voted on at the Annual
Meeting will be filed with the U.S. Securities and Exchange
Commission on a current report on Form 8-K, and such report will be
made available on the Company's SEDAR profile and on the Company’s
website at www.bausch.com.
About Bausch + Lomb Bausch + Lomb is dedicated to
protecting and enhancing the gift of sight for millions of people
around the world – from the moment of birth through every phase of
life. Its comprehensive portfolio of more than 400 products
includes contact lenses, lens care products, eye care products,
ophthalmic pharmaceuticals, over-the-counter products and
ophthalmic surgical devices and instruments. Founded in 1853,
Bausch + Lomb has a significant global research and development,
manufacturing and commercial footprint with approximately 13,000
employees and a presence in nearly 100 countries. Bausch + Lomb is
headquartered in Vaughan, Ontario with corporate offices in
Bridgewater, New Jersey. For more information, visit www.bausch.com
and connect with us on Twitter, LinkedIn, Facebook and
Instagram.
© 2023 Bausch & Lomb Incorporated or its affiliates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230425005469/en/
Investors: Arthur Shannon arthur.shannon@bausch.com
Allison Ryan allison.ryan@bausch.com (877) 354-3705 (toll free)
(908) 927-0735
Media: Lainie Keller lainie.keller@bausch.com (908)
927-1198
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jul 2023 to Jul 2024